KNG1 anticorps (N-Term)

N° du produit ABIN6262859

Détail du produit anti-KNG1 anticorps

Antigène: KNG1 (Kininogen 1 (KNG1))

Épitope: N-Term

Reactivité: Humain, Rat, Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp KNG1 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC), ELISA, Immunocytochemistry (ICC), Immunofluorescence (IF)

Specificité: KNG1 Antibody detects endogenous levels of total KNG1.

Purification: The antiserum was purified by peptide affinity chromatography using SulfoLink^TM Coupling Resin (Thermo Fisher Scientific).

Immunogène: A synthesized peptide derived from human KNG1, corresponding to a region within N-terminal amino acids.

Isotype: IgG

Information d'application

Indications d'application: WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500, ELISA(peptide) 1:20000-1:40000

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: Rabbit IgG in phosphate buffered saline , pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20 °C. Stable for 12 months from date of receipt.

Date de péremption: 12 months

Détails sur KNG1

Antigène: KNG1 (Kininogen 1 (KNG1))

Autre désignation: KNG1 (KNG1 Produits)

Synonymes: anticorps BDK, anticorps BK, anticorps KNG, anticorps Kng, anticorps KNG2, anticorps fb64g01, anticorps wu:fb64g01, anticorps zgc:103569, anticorps kininogen, anticorps bdk, anticorps kng, anticorps KNG1, anticorps IHRP, anticorps KINKG, anticorps KINKH, anticorps Kng1, anticorps Kngk, anticorps kininogen 1, anticorps kininogen 1 L homeolog, anticorps inter-alpha-trypsin inhibitor heavy chain family member 4, anticorps kininogen 2-like 1, anticorps KNG1, anticorps Kng1, anticorps kng1, anticorps kng1.L, anticorps ITIH4, anticorps Kng2l1

Sujet:

Description: 1 Kininogens are inhibitors of thiol proteases, (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII, (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes, (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action), (5) LMW-kininogen inhibits the aggregation of thrombocytes, (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.

Gene: KNG1

Poids moléculaire: 72kDa

ID gène: 3827

UniProt: P01042

Pathways: ACE Inhibitor Pathway, Glycosaminoglycan Metabolic Process